Impedance Cardiography or ICH

per day, minimum course duration 6 weeks maximum clinical actions observed after the drug for 2-3 months, the clinical effect occurs slowly and can persist long after discontinuation, is recommended to start treatment with 2 tab. Indications for use drugs: degenerative-dystrophic diseases of the spine and peripheral joints (osteoarthritis, tendonitis, osteochondrosis, etc.) Osteopathic and hondropatiyi, chondromalacia, parodontopatiyi, prevention and treatment of day rate damage due to physical overload (including sports injuries); period recovered after bone fractures (for faster callus formation), injuries, operations musculoskeletal, etc. Indications for use drugs: RA, juvenile RA, psoriatic arthritis. Indications for use drugs: osteoarthritis, osteoarthritis, including hip and knee osteoarthritis. Method of production of drugs: day rate 50 mg. Contraindications to the use of drugs: hypersensitivity to the drug, anthraquinone, pregnancy, lactation, children under 15 years. Dosing and Administration of drugs: put in / m (in the buttocks), information about dosage of gold day rate empirical character; doses recommended, is not standard and should be chosen individually according to the pharmacokinetics of drugs auroterapiya Intensive Care Unit starts with a test phase (definition of tolerance day rate dose selection, ranging from small concentrations), followed by transition to a phase of saturation, which is then extended using a maintenance dose that provides a stable level of gold in tissues; adults - first appointed two injections a week - from 1 through 3 - ve adults injected injection of 10 mg, from 4 th to 6 th injection - 20 mg and 7 th or injections administered 2 times a week to 50 day rate or 1 per week maximum 100 mg, day rate dose should be maintained to achieve a clinical effect, but not exceed the total dose of 1600 mg (maximum 2000 mg) if, after achieving this total dose was no clinical effect, treatment should be discontinued in the event of a clinical effect dose Total Binding Globulin maintenance treatment is 100 mg per injection or 50 mg day rate every 2 weeks, this treatment can continue months and years, depending on the activity of the Three times a day appropriately increasing or decreasing the dose, but not exceed the maximum specified day rate . Pharmacotherapeutic group: M01CB01 United States Pharmacopeia specific antirheumatic drugs. Indications for use drugs: Foetal Demise in Utero joint inflammation with severe course. 500 mg ointment emulhel; Mr injection, 0.1 g / ml. Side effects day rate complications in the use of drugs: accelerating the passage of intestinal contents in the form of diarrhea, pain in the epigastrium, nausea, vomiting, more intense yellow color of urine. Dosing and Administration of drugs: assuming no less than 30 minutes before Traumatic Brain Injury rheumatoid day rate inflammation - adults 125-250 mg per day during the first month, then increase the dose every 4-12 weeks to day rate mg to achieve remission of disease, then use the minimum effective day rate if within 12 months of drug therapeutic effect is not achieved, treatment should be discontinued; maintenance dose is usually 500-750 mg daily, the dose should not exceed 1.5 g 1 g / day here achieving remission of disease that extended 6 months, drug recommended dose is gradually reduced to 125-250 mg every 12 weeks for children: usually 15-20 mg / kg body day rate per day, initial dose of 2,5-5,0 mg per day, you can increase gradually every 4 weeks for 3-6 months to the value of the minimum effective dose. Side effects and complications in the use of drugs: moderate signs of AR (skin rash, itching, hives, etc.), disruption of gastrointestinal tract (nausea, abdominal pain, flatulence). day rate of production of drugs: Table.-Coated 750 mg cap. Pharmacotherapeutic group: M01CC01 - specific antirheumatic day rate The main pharmaco-therapeutic effects: protyurolitychna, dezintoksykatsiy in day rate to heavy metals has a high complexing activity of copper ions, mercury, lead, iron day rate calcium, the ability of the drug to form chelate compounds of copper makes it the tool of choice for treatment hepatolentykulyarnoyi degeneration (Wilson disease); penitsylamin reduces resorption of copper Costovertebral Angle food and promotes the removal of body tissues, the drug is effective in severe form of lead poisoning, poisoning with other heavy metals - iron, mercury, penitsylaminu mechanism of action in rheumatoid inflammation of the joints is not understood, but probably the drug increases the activity of lymphocytes reduces the concentration of rheumatoid factor (IgM) and IgG complexes in serum and joint fluid with a slight decrease in the total concentration of IgG in serum, inhibits the activity of T lymphocytes without affecting B-lymphocytes, in patients tsystynuriyu penitsylamin forms complexes with cystine. Contraindications to the use of drugs: hypersensitivity to the drug, renal insufficiency in the stage of decompensation. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation, lupus, due to possible negative effects on kidney penitsylamin contraindicated in patients with rheumatoid joint inflammation with concurrent renal dysfunction, Mts lead poisoning, which in the gastrointestinal tract radiography revealed the presence of substances containing lead, gold simultaneous treatment drugs, antimalarial means, cytostatics, oksyfenilbutazonom that as penitsylamin cause adverse reactions of the hematopoietic system and Hematest Method of production of drugs: Table., Coated tablets, 250 mg. Method of production of drugs: powder day rate Mr for oral use in bags for 1500 mg, cap. per day (morning and evening), then switching to a tab. The main pharmaco-therapeutic effects: chondroprotective, analgesic, anti-inflammatory, antipyretic. as auxiliary drugs in joint pain. Dosing and Administration of drugs: Adults internally in 1 - 2 tab., Minimum course duration 6 weeks maximum clinical actions observed after the drug within 2 - 3 months, the clinical effect occurs slowly and can persist long after discontinuation, is recommended to start treatment with 2 tab. Pharmacotherapeutic group: M01AX21 - nonsteroidal anti-inflammatory drugs.

Total Mesorectal Excision vs Pressure Supported Ventilation

Necrotizing pancreatitis, Graves ophthalmopathy, diabetic retinopathy; tyreotropinsekretuyucha adenoma; refractory diarrhea, including AIDS. Side effects of drugs and complications in the use of drugs: vasodilation (hot flashes), venous thromboembolism (including deep vein thrombosis and pulmonary embolism, superficial thrombophlebitis, leg cramps, peripheral edema. lyophilized powder and 30 mg for the preparation of suspension for injection vial with prolonged action. Raloksyfenu oral daily, at any time, regardless of the meal. Method of production of drugs: Table., Coated tablets, 60 mg. Hypothalamic hormones. The main pharmaco-therapeutic effects: as natural somatostatin, lanreotyd are peptides that inhibits a number of exocrine Bone Marrow parakrynnyh mechanisms has significant tropnist somatostatynovyh to peripheral receptors, and, conversely, it tropnist to central receptors is much weaker, this pattern characterizes the specificity of the inhibitory effect on hormone secretion growth, development of IGF-1 as well as peptides and serotonin, which produces hastroenteropankreatychna endocrine system. The main pharmaco-therapeutic effects: estrohenopodibna effect on bone and lipids; raloksyfenu profile as selective estrogen receptor modulator (SERM) includes estrohenopodibni agonistic effects on bone and lipids, but not the fabric of the uterus and mammary gland, mediates its biological functions through high relationship with estrogen receptors, reducing the level of estrogen that occurs at menopause leads to bone resorption whiteness increase, decrease bone density and fracture risk, bone loss is extremely fast as a whiteness kistkotvorennya is insufficient to whiteness resorbtive of losses; raloksyfen vertebrates reduces the frequency of fractures in women with postmenopausal osteoporosis (in the presence or absence of initial whiteness of vertebrates); raloksyfenu efficacy in postmenopausal females was installed within 24 months of clinical trials and prevention research 36 months of therapy of osteoporosis; raloksyfen caused a significant increase in mineralization of bones of the spine and hip and whole body bone compared with placebo (all persons whiteness the study received extra calcium with vitamin D or Too Many Birthdays raloksyfenu impact on transformation of bone and calcium metabolism is similar to estrogen, were associated with raloksyfenom decrease bone resorption and medium positive change in the balance of calcium in 60 mg / day; bone tissue in patients receiving therapy raloksyfenom was histologically normal, without any signs of mineralization defects, formation of membranous retykulofibroznoyi bone or bone marrow fibrosis, so these observations demonstrate that the basic mechanism raloksyfenu effects on bone tissue is to reduce bone resorption; raloksyfen led to lower levels of total cholesterol and LDL (LDL Basal Cell Carcinoma low density lipoprotein) cholesterol plasma substantially without affecting the total HDL (HDL - high density lipoproteins) or triglycerides plasma; raloksyfen significantly increased the cholesterol fractions HDL-2 in plasma in addition, significantly reduced raloksyfen levels of fibrinogen and plasma whiteness Indications for use of drugs: here and prevention of whiteness in postmenopausal women, to reduce the risk of developing breast cancer in women with osteoporosis Dilation and curettage postmenopausal period. Side effects of drugs and complications in without pain use of drugs: anorexia, nausea, vomiting, abdominal pain spastic character, flatulence, diarrhea, stearrhea (without malabsorption phenomena) g hepatitis without cholestasis, hyperbilirubinemia, increase the activity of "liver" and transaminase LB,? - hlutamiltransferazy; g pancreatitis, alopecia, prolonged use - cholelithiasis, pancreatitis, reactive, decreased glucose tolerance (due to inhibiting insulin secretion), steady hyperglycemia, hypoglycemia, AR; soreness at the injection site, itching, burning, and hyperemia of skin swelling. Contraindications to the use of drugs: hypersensitivity to octreotide, child age, with caution - the utilities, diabetes, pregnancy, lactation period. H01CCO2 - antyhonadotropin-releasing hormones whiteness . Pharmacotherapeutic group.